JP2021097695A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021097695A5 JP2021097695A5 JP2021036823A JP2021036823A JP2021097695A5 JP 2021097695 A5 JP2021097695 A5 JP 2021097695A5 JP 2021036823 A JP2021036823 A JP 2021036823A JP 2021036823 A JP2021036823 A JP 2021036823A JP 2021097695 A5 JP2021097695 A5 JP 2021097695A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- mutane
- immunoglobulin
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022152103A JP7477905B2 (ja) | 2015-05-04 | 2022-09-26 | Ｃｄ１３７に特異的なタンパク質 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15166184.0 | 2015-05-04 | ||
| EP15166184 | 2015-05-04 | ||
| JP2017557299A JP6884708B2 (ja) | 2015-05-04 | 2016-05-04 | Ｃｄ１３７に特異的なタンパク質 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017557299A Division JP6884708B2 (ja) | 2015-05-04 | 2016-05-04 | Ｃｄ１３７に特異的なタンパク質 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022152103A Division JP7477905B2 (ja) | 2015-05-04 | 2022-09-26 | Ｃｄ１３７に特異的なタンパク質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021097695A JP2021097695A (ja) | 2021-07-01 |
| JP2021097695A5 true JP2021097695A5 (https=) | 2021-09-16 |
| JP7149363B2 JP7149363B2 (ja) | 2022-10-06 |
Family
ID=53054879
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017557299A Active JP6884708B2 (ja) | 2015-05-04 | 2016-05-04 | Ｃｄ１３７に特異的なタンパク質 |
| JP2021036823A Active JP7149363B2 (ja) | 2015-05-04 | 2021-03-09 | Ｃｄ１３７に特異的なタンパク質 |
| JP2022152103A Active JP7477905B2 (ja) | 2015-05-04 | 2022-09-26 | Ｃｄ１３７に特異的なタンパク質 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017557299A Active JP6884708B2 (ja) | 2015-05-04 | 2016-05-04 | Ｃｄ１３７に特異的なタンパク質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022152103A Active JP7477905B2 (ja) | 2015-05-04 | 2022-09-26 | Ｃｄ１３７に特異的なタンパク質 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11261221B2 (https=) |
| EP (2) | EP3292137B1 (https=) |
| JP (3) | JP6884708B2 (https=) |
| KR (1) | KR102734408B1 (https=) |
| CN (2) | CN114573680A (https=) |
| AU (1) | AU2016258952C1 (https=) |
| CA (1) | CA2980839C (https=) |
| CL (1) | CL2017002767A1 (https=) |
| DK (1) | DK3292137T3 (https=) |
| ES (1) | ES2932425T3 (https=) |
| IL (1) | IL254516B (https=) |
| MX (1) | MX2017014082A (https=) |
| NZ (1) | NZ736560A (https=) |
| PH (1) | PH12017501583B1 (https=) |
| RU (1) | RU2736312C2 (https=) |
| SG (1) | SG11201708339QA (https=) |
| WO (1) | WO2016177762A1 (https=) |
| ZA (1) | ZA201705960B (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2707126C2 (ru) | 2009-12-07 | 2019-11-22 | Пирис Аг | МУТЕИНЫ ЛИПОКАЛИНА 2 ЧЕЛОВЕКА (Lcn2, hNGAL) С АФФИННОСТЬЮ ДЛЯ ОПРЕДЕЛЕННОЙ МИШЕНИ |
| US10526384B2 (en) | 2012-11-19 | 2020-01-07 | Pieris Pharmaceuticals Gmbh | Interleukin-17A-specific and interleukin-23-specific binding polypeptides and uses thereof |
| WO2015177175A2 (en) | 2014-05-22 | 2015-11-26 | Pieris Ag | Novel specific-binding polypeptides and uses thereof |
| JP6839087B2 (ja) | 2015-01-28 | 2021-03-03 | ピエリス ファーマシューティカルズ ゲーエムベーハー | 血管新生に特異的な新規のタンパク質 |
| JP6783797B2 (ja) | 2015-05-04 | 2020-11-11 | ピエリス ファーマシューティカルズ ゲーエムベーハー | 抗がん融合ポリペプチド |
| CN114573680A (zh) | 2015-05-04 | 2022-06-03 | 皮里斯制药有限公司 | Cd137特异性的蛋白 |
| EP3298030B1 (en) * | 2015-05-18 | 2023-01-18 | Pieris Pharmaceuticals GmbH | Anti-cancer fusion polypeptide |
| MX2017014730A (es) | 2015-05-18 | 2018-06-28 | Pieris Pharmaceuticals Gmbh | Muteinas de lipocalina 2 humana con afinidad por glipicano-3 (gpc3). |
| CN108699162A (zh) | 2015-11-30 | 2018-10-23 | 皮里斯澳大利亚有限公司 | 新型抗血管生成融合多肽 |
| TW201725212A (zh) | 2015-12-10 | 2017-07-16 | 第一三共股份有限公司 | 特異性於降鈣素基因相關胜肽的新穎蛋白 |
| WO2018087108A1 (en) * | 2016-11-09 | 2018-05-17 | Pieris Pharmaceuticals Gmbh | Proteins specific for cd137 |
| WO2019185598A1 (en) | 2018-03-26 | 2019-10-03 | 4Sc Ag | Combination comprising hdac inhibitor and cd137 agonist for cancer therapy |
| EP3827019A1 (en) | 2018-07-24 | 2021-06-02 | Inhibrx, Inc. | Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same |
| FI3830120T3 (fi) * | 2018-07-31 | 2023-06-13 | Pieris Pharmaceuticals Gmbh | CD137:lle ja PD-L1:lle spesifinen uusi fuusioproteiini |
| JP7611820B2 (ja) | 2018-10-11 | 2025-01-10 | インヒブルクス バイオサイエンシズ インコーポレイテッド | Ｄｌｌ３シングルドメイン抗体およびその治療用組成物 |
| CN120623346A (zh) | 2018-10-11 | 2025-09-12 | 因荷布瑞克斯生物科学公司 | Pd-1单结构域抗体及其治疗组合物 |
| JP2022504802A (ja) | 2018-10-11 | 2022-01-13 | インヒブルクス インコーポレイテッド | ５ｔ４シングルドメイン抗体およびその治療組成物 |
| SG11202106353VA (en) * | 2019-02-26 | 2021-07-29 | Pieris Pharmaceuticals Gmbh | Novel fusion proteins specific for cd137 and gpc3 |
| EP3946417A1 (en) * | 2019-03-29 | 2022-02-09 | Pieris Pharmaceuticals GmbH | Inhaled administration of lipocalin muteins |
| JP7301155B2 (ja) | 2019-04-12 | 2023-06-30 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | リポカリンムテインを含む二重特異性抗原結合分子 |
| WO2021089588A1 (en) | 2019-11-04 | 2021-05-14 | Pieris Pharmaceuticals Gmbh | Her2/4-1bb bispecific fusion proteins for the treatment of cancer |
| EP4161957A1 (en) | 2020-06-05 | 2023-04-12 | Pieris Pharmaceuticals GmbH | Multimeric immunomodulator targeting 4-1bb |
| JP2023541482A (ja) | 2020-09-18 | 2023-10-02 | ピエリス ファーマシューティカルズ ゲーエムベーハー | バイオマーカー法および使用法 |
| AU2022241940A1 (en) | 2021-03-23 | 2023-10-26 | Pieris Pharmaceuticals Gmbh | Her2/4-1bb bispecific fusion proteins for the treatment of cancer |
| WO2022200478A1 (en) | 2021-03-24 | 2022-09-29 | Pieris Pharmaceuticals Gmbh | Tumor treatment with a 4-1bb/her2-bispecific agent and a her2-targeted tyrosine kinase inhibitor |
| WO2023118497A1 (en) | 2021-12-22 | 2023-06-29 | Pieris Pharmaceuticals Gmbh | Novel il-18 variants |
| WO2023180523A1 (en) | 2022-03-24 | 2023-09-28 | Pieris Pharmaceuticals Gmbh | Process for purifying fusion proteins |
| JP2025532652A (ja) | 2022-09-21 | 2025-10-01 | シージェン インコーポレイテッド | Ｃｄ１３７およびｃｄ２２８に特異的な新規融合タンパク質 |
| EP4644417A4 (en) * | 2022-12-30 | 2026-02-11 | Abclon Inc | AFFICORPS SPECIFICALLY BINDING TO CD137 AND ITS USE |
| WO2025175123A1 (en) | 2024-02-16 | 2025-08-21 | Seagen Inc. | Methods of treating cancer using fusion proteins specific for cd137 and cd228 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE76311T1 (de) | 1986-08-19 | 1992-06-15 | Genentech Inc | Einrichtung und dispersion zum intrapulmonalen eingeben von polypeptidwuchsstoffen und zytokinen. |
| JPH01215289A (ja) | 1988-02-22 | 1989-08-29 | Toa Nenryo Kogyo Kk | 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法 |
| FR2649991B2 (fr) | 1988-08-05 | 1994-03-04 | Rhone Poulenc Sante | Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces |
| US5728553A (en) | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
| MX9605717A (es) | 1994-05-18 | 1998-05-31 | Inhale Therapeutic Syst | Metodos y composiciones para la formulacion de polvo seco de interferones. |
| DE4417598A1 (de) | 1994-05-19 | 1995-12-14 | Max Planck Gesellschaft | Verwendung des Tetracyclinpromotors zur stringent regulierten Produktion von rekombinanten Proteinen in prokaryontischen Zellen |
| AU5132096A (en) | 1995-01-30 | 1996-08-21 | Terrapin Technologies, Inc. | Glubodies - multiplicities of proteins capable of binding a variety of small molecules |
| US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| US6620413B1 (en) | 1995-12-27 | 2003-09-16 | Genentech, Inc. | OB protein-polymer chimeras |
| DE19641876B4 (de) | 1996-10-10 | 2011-09-29 | Iba Gmbh | Streptavidinmuteine |
| WO1998016873A1 (en) | 1996-10-14 | 1998-04-23 | Firm Forsat Ltd. | Method for preparing dispersions of chromogenic components |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| CA2233725A1 (en) | 1998-03-31 | 1999-09-30 | Hemosol Inc. | Hemoglobin-hydroxyethyl starch complexes |
| DK1087778T3 (da) | 1998-06-08 | 2005-12-19 | Hoffmann La Roche | Anvendelse af PEG-IFN-alfa og Ribavirin til behandling af kronisk hepatitis C |
| US6403564B1 (en) | 1998-10-16 | 2002-06-11 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
| DE19926068C1 (de) | 1999-06-08 | 2001-01-11 | Arne Skerra | Muteine des Bilin-Bindungsproteins |
| AU2002335930B2 (en) | 2001-03-09 | 2005-07-28 | Morphosys Ag | Serum albumin binding moieties |
| WO2003029471A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of apolipoprotein d |
| WO2003029462A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
| AU2003264100A1 (en) | 2003-08-25 | 2005-03-10 | Pieris Proteolab Ag | Muteins of a bilin-binding protein with affinity for a given target |
| WO2005019255A1 (en) | 2003-08-25 | 2005-03-03 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
| JP2007284351A (ja) | 2004-07-27 | 2007-11-01 | Osaka Bioscience Institute | アミロイド蛋白質の凝集を抑制する物質とその作用 |
| US7892827B2 (en) | 2004-11-26 | 2011-02-22 | Pieris Ag | Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4) |
| JP2009509535A (ja) | 2005-09-27 | 2009-03-12 | アムニクス， インコーポレイテッド | タンパク様薬剤およびその使用 |
| EP2046820B1 (en) | 2006-08-01 | 2010-10-20 | Pieris AG | Muteins of tear lipocalin and methods for obtaining the same |
| ES2354653T3 (es) * | 2006-08-01 | 2011-03-16 | Pieris Ag | Muteínas de lipocalina lacrimal y procedimientos para obtener las mismas. |
| WO2009052400A1 (en) | 2007-10-19 | 2009-04-23 | Abbott Laboratories | Antibodies that bind to mammalian ngal and uses thereof |
| DK3381933T3 (da) * | 2008-06-24 | 2020-08-03 | Technische Universität München | Muteiner af hngal og relaterede proteiner med affinitet til et givet mål |
| RU2707126C2 (ru) * | 2009-12-07 | 2019-11-22 | Пирис Аг | МУТЕИНЫ ЛИПОКАЛИНА 2 ЧЕЛОВЕКА (Lcn2, hNGAL) С АФФИННОСТЬЮ ДЛЯ ОПРЕДЕЛЕННОЙ МИШЕНИ |
| EP3299386A1 (en) | 2010-08-16 | 2018-03-28 | Pieris Pharmaceuticals GmbH | Binding proteins for hepcidin |
| AU2011331232B2 (en) | 2010-11-15 | 2015-05-07 | Pieris Ag | Muteins of human lipocalin 2 with affinity for Glypican-3 (GPC3) |
| US10526384B2 (en) * | 2012-11-19 | 2020-01-07 | Pieris Pharmaceuticals Gmbh | Interleukin-17A-specific and interleukin-23-specific binding polypeptides and uses thereof |
| HK1213194A1 (zh) | 2013-03-14 | 2016-06-30 | Daiichi Sankyo Co., Ltd. | 用於新型的结合蛋白质pcsk9 |
| AU2015205530B8 (en) | 2014-01-13 | 2019-09-19 | Pieris Pharmaceuticals Gmbh | Multi-specific polypeptide useful for localized tumor immunomodulation |
| JP6839087B2 (ja) | 2015-01-28 | 2021-03-03 | ピエリス ファーマシューティカルズ ゲーエムベーハー | 血管新生に特異的な新規のタンパク質 |
| CR20170425A (es) | 2015-02-18 | 2017-11-22 | Sanofi Sa | Nuevas proteínas específicas para pioverdina y pioquelina |
| JP6783797B2 (ja) | 2015-05-04 | 2020-11-11 | ピエリス ファーマシューティカルズ ゲーエムベーハー | 抗がん融合ポリペプチド |
| CN114573680A (zh) | 2015-05-04 | 2022-06-03 | 皮里斯制药有限公司 | Cd137特异性的蛋白 |
| EP3298030B1 (en) * | 2015-05-18 | 2023-01-18 | Pieris Pharmaceuticals GmbH | Anti-cancer fusion polypeptide |
| MX2017014730A (es) | 2015-05-18 | 2018-06-28 | Pieris Pharmaceuticals Gmbh | Muteinas de lipocalina 2 humana con afinidad por glipicano-3 (gpc3). |
| WO2018087108A1 (en) | 2016-11-09 | 2018-05-17 | Pieris Pharmaceuticals Gmbh | Proteins specific for cd137 |
-
2016
- 2016-05-04 CN CN202210118268.XA patent/CN114573680A/zh active Pending
- 2016-05-04 US US15/571,611 patent/US11261221B2/en active Active
- 2016-05-04 DK DK16721149.9T patent/DK3292137T3/da active
- 2016-05-04 EP EP16721149.9A patent/EP3292137B1/en active Active
- 2016-05-04 JP JP2017557299A patent/JP6884708B2/ja active Active
- 2016-05-04 CN CN201680025274.3A patent/CN107820500B/zh active Active
- 2016-05-04 ES ES16721149T patent/ES2932425T3/es active Active
- 2016-05-04 EP EP22193830.1A patent/EP4177262A1/en not_active Withdrawn
- 2016-05-04 WO PCT/EP2016/059959 patent/WO2016177762A1/en not_active Ceased
- 2016-05-04 PH PH1/2017/501583A patent/PH12017501583B1/en unknown
- 2016-05-04 SG SG11201708339QA patent/SG11201708339QA/en unknown
- 2016-05-04 RU RU2017135599A patent/RU2736312C2/ru active
- 2016-05-04 KR KR1020177034948A patent/KR102734408B1/ko active Active
- 2016-05-04 NZ NZ736560A patent/NZ736560A/en unknown
- 2016-05-04 MX MX2017014082A patent/MX2017014082A/es unknown
- 2016-05-04 CA CA2980839A patent/CA2980839C/en active Active
- 2016-05-04 AU AU2016258952A patent/AU2016258952C1/en active Active
-
2017
- 2017-09-01 ZA ZA2017/05960A patent/ZA201705960B/en unknown
- 2017-09-14 IL IL254516A patent/IL254516B/en unknown
- 2017-11-02 CL CL2017002767A patent/CL2017002767A1/es unknown
-
2021
- 2021-03-09 JP JP2021036823A patent/JP7149363B2/ja active Active
-
2022
- 2022-01-19 US US17/579,392 patent/US12195503B2/en active Active
- 2022-09-26 JP JP2022152103A patent/JP7477905B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021097695A5 (https=) | ||
| JP7181612B2 (ja) | アルカリ安定性免疫グロブリン結合タンパク質 | |
| JP5480558B2 (ja) | 改善された特異性を有する新規免疫グロブリン結合タンパク質 | |
| JP5812303B2 (ja) | 酸性域での親和性が低下したプロテインａ変異型タンパク質及び抗体捕捉剤 | |
| CA2135208C (en) | Immunoglobulin binding proteins derived from l protein and their uses | |
| JP5229888B2 (ja) | 弱酸性域での易解離性を向上したプロテインａ変異型タンパク質及び抗体捕捉剤 | |
| JP2021007390A5 (https=) | ||
| JP2023504914A5 (https=) | ||
| Gallizia et al. | Production of a soluble and functional recombinant streptavidin inescherichia coli | |
| JP2008532549A (ja) | 内因性クロストリジウム毒素受容体系に対する増大した標的能力を有する修飾クロストリジウム毒素 | |
| JP2003534013A5 (https=) | ||
| EP3054009A1 (en) | PROTEIN COMPRISED BY LINKING BY LINKER MULTIPLE DOMAINS HAVING AFFINITY FOR PROTEINS HAVING Fc PART OF IMMUNOGLOBULIN G (IgG) | |
| JP2019163270A (ja) | 親和性タンパク質及びその使用 | |
| WO2013018880A1 (ja) | プロテインgの細胞膜外ドメイン変異体のタンデム型多量体から成る新規な改変型タンパク質 | |
| Hass et al. | Preparation of synthetic polypeptide domains of carcinoembryonic antigen and their use in epitope mapping | |
| Kojouharova et al. | Differential binding of IgG and of a HIV gp41 peptide by the B chain and A chain globular head sequences of C1q, respectively | |
| JP2024526356A5 (https=) | ||
| CA2096953A1 (en) | Immunoglobulin-binding proteins and recombinant dna molecules coding therefor | |
| JP2004500055A5 (https=) | ||
| WO2024119434A1 (zh) | 一种提高重组蛋白表达效率的酸性表面助溶短肽标签 | |
| JP2025525305A5 (https=) | ||
| CN109504667B (zh) | Irak-m多克隆抗体及其制备方法 | |
| Li et al. | Soluble expression and affinity purification of functional domain of human acetylcholine receptor α-subunit by the modulation of maltose binding protein | |
| Popplewell et al. | Synthesis and mutagenesis of an IgG-binding protein based upon protein A of Staphylococcus aureus | |
| CN103012576B (zh) | 一种c-反应蛋白及其制备和应用 |